The 51-year-old even had to slam rumors of being anorexic in 2009. But in April 2024, she admitted to using Mounjaro — a Type ...

When it comes to medically assisted weight loss, there’s two main schools of thought: either weight loss drugs, like the ...

It appears an unintended side effect of the drug has now struck some of Britain's known suitmakers, who are fed up with ...

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat substance abuse disorders, psychosis, infections, cancer, and dementia.

Tirzepatide, the main ingredient in Mounjaro and Zepbound ... Semaglutide, the main ingredient in Ozempic and Wegovy, is in ongoing shortage, the FDA says, and compounded versions of these ...

The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health ...

Millions of obese Americans have achieved successful weight loss through use of glucagon-like peptide-1 agonists (GLP-1), a game-changing class of obesity medications. Results are often dramatic, but ...